Reality Check on Multiple Myeloma
Market access for multiple myeloma treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: More than 76% of the covered lives under Medicare formularies are restricted
- Class Trends: The FDA granted an additional indication to Darzalex (daratumumab) in combination with Velcade (bortezomib), melphalan and prednisone for people with newly diagnosed multiple myeloma who are not eligible for an autologous stem cell transport
- Key Findings: A variety of novel drugs are being studied for the treatment of relapsed myeloma and relapsed, refractory myeloma
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.